Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle
Gossamer Bio, Inc. surged 46.6% on Monday, boosted by FDA feedback backing a planned seralutinib submission in September. Shares finished at $0.1994. The rally continued premarket.
